The clinical significance of anaplastic features, a rare event in pilocytic astrocytoma (PA), is not fully established. We reviewed 34 PA with anaplastic features (Male = 21, Female = 13; median age 35 y, 5 to 75) among approximately 2200 PA cases (1.7%). Tumors were included which demonstrated brisk mitotic activity [at least 4 mitoses/10 high power fields (400 Â )], in addition to hypercellularity and moderateto-severe cytologic atypia, with or without necrosis. The tumors either had a PA precursor, coexistent (n = 14) (41%) or documented by previous biopsy (n = 10) (29%), or exhibited typical pilocytic features in an otherwise anaplastic astrocytoma (n = 10) (29%). Clinical features of neurofibromatosis type-1 were present in 24% and a history of radiation for PA precursor in 12%. Histologically, the anaplastic component was classified as pilocytic like (41%), small cell (32%), epithelioid (15%), or fibrillary (12%). Median MIB1 labeling index was 24.7% in the anaplastic component and 2.6% in the precursor, although overlapping values were present. Strong p53 staining (3+) was limited to areas with anaplasia (19%), with overlapping values for 1 and 2+ in areas without anaplasia. Median overall and progression-free survivals after diagnosis for the entire study group were 24 and 14 months, respectively. Overall and progression-free survivals were shorter in the setting of prior radiation for a PA precursor (P = 0.007, 0.028), increasing mitotic activity (P = 0.03, 0.02), and presence of necrosis (P = 0.02, 0.02), after adjusting for age and site. The biologic behavior of PAs with high-mitotic rates and those with necrosis paralleled that of St Anne-Mayo grades 2 and 3 diffuse astrocytomas, respectively. In summary, PA with anaplastic features exhibits a spectrum of morphologies and is associated with decreased survival when compared with typical PA.
P ilocytic astrocytoma (PA) is a World Health Organization (WHO) grade I tumor typically affecting children and young adults. As the most common brain tumor of childhood, its estimated incidence in the United States is 0.87 per 100,000 individuals under 19 years of age 11 The cerebellum is most often affected, 22 but PA may occur along the entire neuraxis with a proclivity for certain sites (optic pathways, hypothalamus, basal ganglia, brainstem, cerebral hemispheres, and spinal cord). In addition, PA is the most frequently occurring central nervous system tumor in association with neurofibromatosis type-1 (NF1). In this setting, PA tends to involve the optic pathways and typically has a particularly favorable prognosis, 27 spontaneous involution occurring in some instances. 24 The behavior of PA is generally favorable with 5 and 10-year overall survival rates greater than 95% after surgical intervention alone. 8, 14, 22 Key prognostic factors include patient age and extent of resection. 14, 32 Progression and recurrence resulting in death occur in a small subset of cases despite typical histologic features. 3, 6, 20 Pilomyxoid astrocytoma, a recently recognized PA variant, shows a predilection for the hypo thalamic region of young children, tends to undergo leptomeningeal dissemination, and is associated with a worse prognosis. 34 With diffusely infiltrating astrocytomas histologic progression to higher grade tumors is frequent, although to a lesser extent in the pediatric population. 7, 21 Conversely, histologic progression in PA as well as the presence of anaplastic features are rare findings. Some authors even doubt the potential for anaplastic change in PA, proposing that PA are hamartomatous rather than neoplastic lesions. 23 Published descriptions of anaplastic features in PA consist mainly of isolated case reports and small series. 2, 4, 9, 10, 13, [18] [19] [20] [29] [30] [31] [32] [35] [36] [37] Many, but not all examples, have occurred in association with prior irradiation of a benign PA. 2, 4, 9, 19, [29] [30] [31] 35, 36 Clinical behavior is often unpredictable: some patients do poorly, whereas others remain stable, even with disseminated leptomeningeal disease. 1 This study evaluates our experience of PA with anaplastic features, describes their histologic spectrum, and attempts to establish practical morphologic definitions.
MATERIALS AND METHODS Patients
A search was performed for PA with anaplastic features accessioned in the Mayo Clinic Pathology records between 1985 and 2008. Cases of PA with anaplastic features (n = 10) or with documented prior WHO grade I PA (n = 24) were included. Majority (30 cases) were identified among 1591 PA consults (1.8%). The remaining 4 tumors were obtained from 644 patients with PA, representing 0.6% of all PA operated at Mayo Clinic. Slides from original precursor lesions and from multiple surgical procedures were available for review in 11 cases (32%). Follow-up information was gathered from medical records, consultation letters, and online death registries. The study was approved by the Mayo Clinic Institutional Review Board.
Pathology and Inclusion Criteria
Cases were reviewed by 4 neuropathologists (P.C.B., C.G., F.J.R., and B.W.S.), with the exception of 6 consultation cases which were reviewed by 3. Tumors were included if they demonstrated brisk mitotic activity [at least 4 mitoses/10 high power fields (HPF) (Â 400)], in addition to hypercellularity and moderate-to-severe cytologic atypia, with or without necrosis. For case inclusion, anaplastic features were required to occupy at least one low-power field (20 Â). In addition some features typical of PA had to be present, in at least one low-power field (20 Â), including compact piloid astrocytes and/or microcystic zones, Rosenthal fibers, and eosinophilic granular bodies (Figs. 1A-C). High-grade astrocytomas arising after treatment for a PA, but lacking a distinct coexistent PA precursor or at least some histologic features typical of PA were excluded.
Upon review of all available slides, the cases were included in the study if at least 3 neuropathologists agreed with the diagnosis of PA with anaplastic features. Histologic features were graded as previously described. 26 In brief, nuclear atypia was graded on a 3-tiered scale based on chromatin and nuclear irregularities of nondegenerative type. Cellularity was rated as low, moderate, or high as previously described. 26 Degree of invasiveness was classified as absent, partial, or diffuse based upon axonal density on neurofilament protein immunostains when available, in combination with the identification of entrapped neurons and/or axons on hematoxylin and eosin stain. Mitotic indices were calculated by counting the number of mitoses/10 HPF (400 Â) using an Olympus BH-2 microscope. We excluded optic pathway tumors in NF1-associated cases as elevated mitotic activity and hypercellularity are commonly seen in this group and are not associated with an adverse outcome. 26 
Immunohistochemistry
Immunohistochemical stains used the Dual Link Envision+ (Dako) detection system and a DAKO Autostainer (Dako North America, Inc, Carpinteria, CA). Antigen retrieval employed ethylenediaminetetra-acetic acid and diaminobenzidine served as the chromogen. The various antibodies used were directed against the following antigens: glial fibrillary acidic protein (polyclonal, 1:4000; Dako, Carpinteria, CA), neurofilament protein (clone 2F11, 1:75; Dako), p53 protein (clone DO7, 1:2000; Dako), INI-1-BAF47 (clone 25, 1:100; BD Transduction, BD Biosciences, San Jose, CA), and Ki-67 (clone MIB-1, monoclonal, 1:300; Dako). Whenever feasible, immunoreactivity for p53 protein was evaluated in both the anaplastic and benign-appearing tumor components. As previously reported, 15 p53 protein stain was scored on the following semiquantitative scale: no staining (0), strong focal staining of <10% of cells (1+), strong staining of 10% to 50% of cells or weak staining of >50% of cells (2+), and strong staining of >50% of cells (3+). Quantitative evaluation of MIB-1 labeling indices was performed using the Hamamatsu NanoZoomer Digital Pathology for scanning images and IHCScore software for computer-assisted analyses (Bacus Laboratories, Lombard, IL).
Statistics
Patient and tumor characteristics were described using frequencies and percentages, or medians, ranges and interquartile ranges as appropriate. Overall and recurrence-free survivals were calculated from the best estimated time of development of anaplastic changes to time of death or recurrence (respectively). Overall and recurrence-free survivals were illustrated using Kaplan-Meier survival curves along with estimates and 95% confidence intervals (CI) for median survival. Survival and recurrence-free survivals were compared between clinicopathologic groups using Cox proportional hazards regression, adjusted for age, sex, and/or site of tumor. Hazard ratios and their 95% CI were estimated. If a precise date of recurrence was unknown, but the patient died within 3 years of the appearance of anaplastic features, the day of death was considered the recurrence date. Statistical analyses were performed using SAS version 9 software (SAS Institute Inc, Cary, NC). All two-sided P values <0.05 were considered statistically significant.
RESULTS

Clinical Features of PA With Anaplastic features
Clinical features are summarized in Table 1 . The patients included 13 females and 21 males. The median age at diagnosis of PA with anaplastic features was 35 years (range: 5 to 75 y). Six (18%) were pediatric cases (patients <18 y old). Fifty percent of tumors arose in the cerebellum, whereas 35% were supratentorial. Information regarding preoperative radiologic imaging was available in 24 cases (71%). Studies included magnetic resonance imaging in 14 (58%), computed tomography in 4 (17%), and unspecified methods in 6 (25%). Leptomeningeal dissemination was documented in only 1 instance. Information regarding postoperative treatment modalities was available in 16 patients (47%).
Postoperative treatment approaches to PA with anaplastic features included radiation therapy in 13 (81%) and chemotherapy in 11 (69%), including temozolomide in 7 (44%). Two patients underwent Gliadel wafer (Eisai Corporation of North America) placement. In 3 cases (19%) the patients were followed with observation alone. A PA precursor was documented at an earlier time in 10 cases (29%); the median time between original diagnosis and diagnosis of PA with anaplastic features was 14 years in this group (range: 4 mo to 40 y). Only 4 of these 10 
Histologic and Immunohistochemical Features of PA With Anaplastic Features
A total of 3 neuropathologists agreed with the diagnosis in all cases and 4 in 88% of cases. Histologic features are summarized in Table 2 and illustrated in Figures 1 and 2 . The most common histologic pattern was ''pilocytic like'' (41%), that is featuring compact, bipolar cells with Rosenthal fibers, and/or microcysts with eosinophilic granular bodies, but with brisk mitotic activity and hypercellularity (Figs. 1D, G). The next most frequent pattern was that of a poorly differentiated, small cell process (32%) ( Fig. 1F ) which was glial fibrillary acidic protein immunoreactive (11 of 11 cases). Epithelioid or rhabdoid patterns were the third most frequent (15%) ( Fig. 1E ), followed by cytologic features of fibrillary astrocytoma in 12% ( Fig. 1H and Fig. 2 ). Immunohistochemical stains for INI-1-BAF-47 performed in 3 (of 5) tumors with epithelioid/rhabdoid cytology showed preservation of nuclear immunoreactivity (not shown). p53 overexpression (3+) was present in the anaplastic component in 4 (of 21) cases tested (19%), but not in the PA precursors. Median MIB1 labeling index was 24.7% (range: 4.44 to 62.5).
Focal anaplastic features in the form of hypercellularity and brisk mitotic activity (5 and 10 per 10 HPF, respectively) found in a single low-power field was noted in one brainstem and one cerebellar example each ( Fig. 3 ). Both patients are well without evidence of disease, respectively 13 and 27 months after gross total resection alone. By comparison, in the rest of the group anaplastic features were multifocal or widespread. NF1-associated PA NF1-association among PA with anaplastic features study group was noted in 8 (24%) cases, 3 initially presenting as PA and 5 PA with anaplastic features (Table 3 ). Imaging and pathologic features of a representative case are illustrated in Figure 4 . None of the tumors received radiation therapy before the diagnosis of PA with anaplastic features. Median patient age in the entire NF1 patient group was 35 years (range: 11 to 59 y). Follow up was available in 6 patients (75%); 3 developed recurrences at 2, 10, and 11 months and 2 patients died of disease, respectively 12 and 24 month postsurgery. Finally, 1 patient developed what appeared to be radiation necrosis on perfusion magnetic resonance imaging at 9 months and 2 patients are alive without evidence of disease at 1 and 13 years. The one patient alive without evidence of disease at 1 year received Avastin in combination with radiation therapy and camptothecin-11 after having undergone a gross total resection. After adjusting for age and site, no difference in recurrence-free (P = 0.83) or overall survival (P = 0.50) was noted between the NF1 group and patients with sporadically occurring tumors.
Survival Analysis of PA With Anaplastic Features
Survival data with clinical follow up was available in 28 patients (82%). Median overall and progression-free survivals for the entire group were 24 months (95% CI: 17-29) and 14 months (95% CI: 11-29), respectively. Events included 19 deaths and 19 recurrences in 28 patients. Increasing patient age was inversely correlated with overall survival [hazard ratio (HR) = 1.03, P = 0.02]. There were no prognostic differences by tumor site (cerebellar vs. noncerebellar locations) (P>0.05), but we chose to adjust for this parameter, given the recently identified biologic differences of PA from different sites. 38 After adjusting for age and tumor site, the following variables were found to be associated with decreased overall and progression free-survivals, respectively: history of prior radiation (P = 0.007, 0.028), history of a PA precursor (P = 0.02, 0.02), mitoses/10 HPF as a continuous variable (P = 0.03, 0.02), and necrosis of any kind (P = 0.02, 0.02) ( Fig. 5 ). Adjusted for age and tumor site, greater than 5 mitoses/10 HPF and severe cytologic atypia were associated with decreased progression-free (P = 0.04 and 0.02, respectively), but not with overall survival. After adjusting for age and tumor site, there were no statistically significant associations (P>0.05) with presence of NF1, tumor location, date of diagnosis (comparing patients treated before or after 2000), tumor cellularity, presence of atypical mitoses, endothelial proliferation, degree of parenchymal infiltration, microscopic leptomeningeal involvement, cytologic type of the malignant component, extent of resection, or the administration of postoperative temozolomide chemotherapy.
Survival Analysis Comparing With Other Astrocytoma Subtypes
To evaluate overall survival in the context of other astrocytoma subtypes, survival data was obtained from the historical cohort used to established St Anne-Mayo grading of astrocytomas, which was later used as the basis of the WHO grading of diffuse astrocytomas. 12 That study included conventional PAs (n = 51), as well as grade 2 (n = 46), grade 3 (n = 51), and grade 4 (n = 188) diffusely infiltrative astrocytomas. The results of the survival analyses are summarized in Table 4 and illustrated in Figure 6 . In brief, survival in our entire patient cohort (reference group) was worse than that associated with conventional PAs (HR = 0.11, P< 0.0001) and better than grade 4 astrocytomas (HR = 3.20, P<0.0001). It was, however, not statistically different from the survival of patients with grade 2 or grade 3 astrocytoma. When subdividing our current patient cohort according to the presence or absence of necrosis, survival in PA with anaplastic features without necrosis was: no different from that associated with St Anne-Mayo grade 2 astrocytomas (P = 0.44), better, but not significantly (P = 0.0943) than grade 3 astrocytoma patients, and significantly better than grade 4 astrocytomas (P = 0.0004). Patients with necrosis-associated tumors had overall survivals worse than grade 2 astrocytomas (P = 0.01), not significantly different to those with grade 3 astrocytoma (P = 0.40), but better than grade 4 astrocytomas (P = 0.002).
DISCUSSION
PAs are low-grade tumors of an indolent nature with little potential for malignant transformation. The literature contains no firm histologic criteria for a diagnosis of PA with anaplastic features. In Table 5 we have summarized the literature regarding cases of PA with anaplasia providing data regarding specific histologic features. Reported examples lacking sufficient histologic descriptions of either a PA precursor 25, 40 or features of PA with anaplasia 5,30,37 were excluded. In that some tumors, particularly in the older literature, were simply referred to as ''cerebellar astrocytoma,'' it is unclear whether they represented pilocytic or diffuse infiltrative astrocytomas. For example, Kepes et al 18 reported the dramatic example of an infiltrating astrocytoma of the cerebellum with microcysts and anaplastic features in a 9-year-old boy. The tumor had undergone widespread 32 defined criteria of anaplastic transformation, including brisk mitotic activity and palisading necrosis. The changes, present in 14% of their cases, suggested that anaplastic transformation occurs more frequently in adults. This is in keeping with our findings that the median age at development of anaplasia in an unselected series was 35 years. An interesting finding of our study is that a history of radiation was present in only a minority of the cases (11%). This differs from the literature, in which the majority of PA with anaplastic features are associated with a history of irradiation of a PA precursor ( Table 5) . One possible explanation is that most tumors in our series were consultation derived and posed the challenge of diagnosing primary PA with anaplastic features. In any case, both the occurrence of a precursor PA at an earlier date and a history of prior irradiation, were associated with a less favorable prognosis. These findings suggest that tumors developing postradiation are biologically distinct from those developing anaplastic features spontaneously in a PA precursor. It is still possible that some of these cases represent separate second primaries, although by only including in this setting tumors that had at least partial, coexistent typical pilocytic features, we attempted to minimize this possibility. This approach further explains the small number of postradiation PA with anaplastic features in our series compared with the literature.
This study indicates that PA with anaplastic features is associated with decreased patient survival. We found it useful to compare our data with a large, published clinicopathologic study of pilocytic and diffusely infiltrative astrocytomas. 12 Tumors in that published series 12 were graded according to the St Anne-Mayo scheme, the criteria which were later adopted into the WHO. 21 The approach was binary and included the presence or absence of nuclear atypia, mitotic activity, strictly defined endothelial proliferation, and necrosis of any type. The results of these comparisons should be viewed with caution, given the differing decades during which the patients were treated and the relatively smaller number of tumors studied in our current series. In addition, St Anne-Mayo and WHO grading schemes should not be equated. The current WHO classification 21 requires more than one mitosis for a diagnosis of anaplastic astrocytoma (WHO grade III), whereas a single mitosis was sufficient for a grade 3 designation in the St Anne-Mayo grade scheme. In a prior study we found that infiltrating astrocytomas with a solitary mitosis had a better prognosis than those with greater numbers of mitoses. 16 This may have some confounding effects in our study, although astrocytomas with a solitary mitosis represent only a minority of grade 3 astrocytomas in the St Anne-Mayo scheme (approximately 24% in one study). 16 These caveats aside, we found PA with anaplastic features without necrosis to behave closer to St Anne-Mayo grade 2 astrocytoma, whereas the presence of necrosis in a mitotically active PA conferred a behavior analogous to that of grade 3 astrocytoma, but better than grade 4.
As compared with diffusely infiltrating astrocytomas, the histologic characteristics indicative of PA with anaplastic features differ somewhat. Necrosis without pseudopalisading is said to occur in approximately 10% of cases and to be of no prognostic significance in some studies, 16 although it was associated with decreased event-free survival in a recent study. 33 The same is true of only occasional mitoses and microvascular proliferation. 16 Our study further focused upon all these parameters, finding that mitotic activity exceeding 4/10 HPF, other than as a microscopic focal feature, defined as a single low-power field (20 Â), is of prognostic significance, distinguishing PA with anaplastic features from conventional, WHO grade I PAs. We used this mitotic index cutoff because it was the lowest mitotic rate found in PA with anaplastic features in our files. As the survival of patients with PA showing increased mitotic activity but lacking necrosis is no worse as a group than that of patients with grade 2 infiltrating astrocytomas, with the caveats mentioned above, the designation of atypical PA may be appropriate. Further studies will be required to confirm our findings and formulate minimal criteria for the diagnosis.
Our study included 2 cases in which anaplastic features of hypercellularity and increased mitotic activity were focal; these tumors did not behave in an aggressive manner. It is also of note that the presence of conventional or pseudopalisading necrosis, an important histologic component of PA with anaplastic features, does not equate with the behavior of glioblastoma. We do not, therefore, apply the term glioblastoma or attribute a grade IV designation to pilocytic tumors with anaplastic features featuring necrosis.
With regards to NF1, 8 of our patients (22%) satisfied clinical criteria for the syndrome. As previously noted, we purposely excluded tumors of the optic pathways, because they represent a clinicopathologically unique niche in NF1 patients, 38 often being associated with a favorable outcome, regardless of specific histologic features. 26 Nonetheless, fully half of NF1-associated PA with anaplastic features in our series arose in the cerebellum. It is of note that early studies of NF1associated gliomas found cerebellar tumors to behave less favorably. 17, 28 In that many such studies antedated current glioma and neurofibromatosis classification schemes, some of these early tumors may have represented diffusely infiltrating astrocytomas or even ependymomas in NF2.
The main limitation of our study is the frequent lack of detailed clinical and therapeutic as well as follow-up data. This is often a problem in studies of rare tumors available only in large consultation services. Acquiring case numbers sufficient to arrive at solid, scientific generalizations is often impossible in single, even large, institutions. Nonetheless, we have studied the largest cohort to date of PA with anaplastic features patients. Our data suggest that such tumors behave in a more aggressive manner than conventional PA. Despite exhibiting morphologic features common to high-grade, diffuse, or infiltrative astrocytic tumors, PA with anaplastic features do not exhibit the same correlation between morphologic features and tumor behavior. Moreover, even ''high-grade'' PA with anaplastic features does not behave like glioblastoma. At best, PA with anaplastic features with the requisite mitotic index (>4/10 HPF), as well as those featuring necrosis, may behave as a diffuse low-grade or anaplastic astrocytoma, respectively. Increased recognition of low and high-grade lesions may prove useful for therapeutic stratification. Similarly, it may shed light on the molecular mechanisms underlying their genesis.
